PriceTargets.com logo

Itamar Medical - ITMR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$30.87 As of 12/16/2021 01:00 AM ET
+0 (0.00%)
Get New Itamar Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITMR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITMR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Itamar Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $30.87.

This chart shows the closing price for ITMR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Itamar Medical. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/16/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/20/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$30.00 ➝ $31.00
9/15/2021LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$33.85
9/14/2021Alliance Global PartnersDowngradeBuy ➝ Neutral
9/14/2021CowenDowngradeOutperform ➝ Market Perform$30.00 ➝ $31.00
9/14/2021HC WainwrightDowngradeBuy ➝ Neutral$36.00 ➝ $31.00
9/13/2021HC WainwrightReiterated RatingBuy ➝ Buy$36.00
5/20/2021Leerink PartnersLower TargetOutperform$33.00 ➝ $30.00
3/8/2021HC WainwrightBoost TargetBuy$30.00 ➝ $36.00
3/2/2021Piper SandlerBoost TargetOverweight$26.00 ➝ $30.00
1/11/2021HC WainwrightReiterated RatingBuy$30.00
12/17/2020HC WainwrightReiterated RatingBuy$30.00
11/18/2020HC WainwrightBoost TargetBuy$28.00 ➝ $30.00
10/14/2020Alliance Global PartnersBoost Target$28.00 ➝ $29.00
8/17/2020HC WainwrightBoost TargetPositive ➝ Buy$21.00 ➝ $28.00
8/3/2020CowenReiterated RatingBuy$30.00
7/28/2020CowenReiterated RatingBuy$30.00
6/18/2020CowenBoost TargetOutperform$20.00 ➝ $27.00
6/12/2020Leerink PartnersInitiated CoverageOutperform$30.00
5/28/2020Alliance Global PartnersBoost TargetBuy$17.75 ➝ $22.75
5/28/2020HC WainwrightReiterated RatingBuy$21.00
5/4/2020HC WainwrightReiterated RatingBuy$21.00
4/15/2020Alliance Global PartnersLower Target$19.50 ➝ $17.75
4/13/2020Piper SandlerReiterated RatingBuy$22.00
3/31/2020CowenInitiated CoverageOutperform$20.00
3/23/2020HC WainwrightInitiated CoverageBuy$21.00
(Data available from 3/16/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Itamar Medical logo
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.
Read More

Today's Range

Now: $30.87
Low: $30.87
High: $30.87

50 Day Range

MA: $30.75
Low: $30.54
High: $30.87

52 Week Range

Now: $30.87
Low: $16.36
High: $30.91

Volume

N/A

Average Volume

90,796 shs

Market Capitalization

$497.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Itamar Medical?

The following Wall Street research analysts have issued stock ratings on Itamar Medical in the last year:
View the latest analyst ratings for ITMR.

What is the current price target for Itamar Medical?

0 Wall Street analysts have set twelve-month price targets for Itamar Medical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Itamar Medical in the next year.
View the latest price targets for ITMR.

What is the current consensus analyst rating for Itamar Medical?

Itamar Medical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ITMR.

What other companies compete with Itamar Medical?

Other companies that are similar to Itamar Medical include Azenta, Harmony Biosciences, CONMED, PACS Group and Arrowhead Pharmaceuticals. Learn More about companies similar to Itamar Medical.

How do I contact Itamar Medical's investor relations team?

The company's listed phone number is (724) 617-7000. The official website for Itamar Medical is www.itamar-medical.com. Learn More about contacing Itamar Medical investor relations.